Replies to post #124495 on Biotech Values

[jq1234]

NVO executives talked up the competitive offerings from SNY while dismissing LLY as barely more than an afterthought.

It shows insulin is price sensitive, especially when they are not differentiated.

Insulin sales were hurt by the impact of health-care reforms in the U.S., Germany, Spain and Turkey, and by the loss of contracts in the U.S., where Lilly has been pursuing an “aggressive” pricing strategy, Chief Executive Officer Lars Rebien Soerensen said on a conference call with analysts.